Vitamin D, nervous system and aging

Psychoneuroendocrinology

Volumn 34, Issue SUPPL. 1, 2009, Pages

  Tuohimaa, P ^a,b   Keisala, T ^a   Minasyan, A ^a   Cachat, J ^c   Kalueff, A ^c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcidiol; Calcitriol; Nervous system; Neurodegeneration; Premature aging; Vitamin D

Indexed keywords

24,25 DIHYDROXYCOLECALCIFEROL; CALCIFEDIOL; CALCITRIOL; COLECALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; VITAMIN D;

AGING; ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS; HUMAN; HYPERTENSION; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NEUROLOGIC DISEASE; NONHUMAN; OSTEOPOROSIS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PREMATURE AGING; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SEASONAL AFFECTIVE DISORDER; SOLID TUMOR; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

AGING; AGING, PREMATURE; ANIMALS; CALCIFEDIOL; CENTRAL NERVOUS SYSTEM; CHOLECALCIFEROL; CHRONIC DISEASE; ERGOCALCIFEROLS; HUMANS; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 71249144773     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2009.07.003     Document Type: Article

References (115)

1. Akutsu N., Lin R., Bastien Y., Bestawros A., Enepekides D.J., Black M.J., and White J.H. Regulation of gene expression by 1alpha,25-dihydroxyvitamin D3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol. Endocrinol. 15 (2001) 1127-1139
2. Atkins G.J., Anderson P.H., Findlay D.M., Welldon K.J., Vincent C., Zannettino A.C., O'Loughlin P.D., and Morris H.A. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 40 (2007) 1517-1528
3. Barnevik-Olsson M., Gillberg C., and Fernell E. Prevalence of autism in children born to Somali parents living in Sweden: a brief report. Dev. Med. Child Neurol. 50 (2008) 598-601
4. Bordier P., Rasmussen H., Marie P., Miravet L., Gueris J., and Ryckwaert A. Vitamin D metabolites and bone mineralization in man. J. Clin. Endocrinol. Metab. 46 (1978) 284-294
5. Bouillon R., Bischoff-Ferrari H., and Willett W. Vitamin D and health: perspectives from mice and man. J. Bone Miner. Res. 23 (2008) 974-979
6. Bouillon R., Carmeliet G., Verlinden L., van Etten E., Verstuyf A., Luderer H.F., Lieben L., Mathieu C., and Demay M. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 29 (2008) 726-776
7. Brachet P., Neveu I., Naveilhan P., Garcion E., and Wion D. Vitamin D, a neuroactive hormone: from brain development to pathological disorders. In: Feldman Pa.G. (Ed). Vitamin D. Second edition (1997), Academic Press, San Diego, CA
8. Bransby E.R., Berry W.T., and Taylor D.M. Study of the vitamin-D intakes of infants in 1960. Br. Med. J. 1 (1964) 1661-1663
9. Brewer L.D., Porter N.M., Kerr D.S., Landfield P.W., and Thibault O. Chronic 1alpha,25-(OH)2 vitamin D3 treatment reduces Ca2+-mediated hippocampal biomarkers of aging. Cell Calcium 40 (2006) 277-286
10. Brookes E.B., and Morrison A.W. Vitamin D deficiency and deafness. Br. Med. J. (Clin. Res. Ed.) 283 (1981) 273-274
11. Brown A.J., Dusso A., and Slatopolsky E. Vitamin D. Am. J. Physiol. 277 (1999) F157-F175
12. Brown-Borg H.M. Hormonal control of aging in rodents: the somatotropic axis. Mol. Cell. Endocrinol. (2008)
13. Buell J.S., Scott T.M., Dawson-Hughes B., Dallal G.E., Rosenberg I.H., Folstein M.F., and Tucker K.L. Vitamin D is associated with cognitive function in elders receiving home health services. J. Gerontol. A: Biol. Sci. Med. Sci. (2009)
14. Cannell J.J. Autism and vitamin D. Med. Hypotheses 70 (2008) 750-759
15. Cantorna M.T. Vitamin D and multiple sclerosis: an update. Nutr. Rev. 66 (2008) S135-S138
16. Cantorna M.T., Zhu Y., Froicu M., and Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am. J. Clin. Nutr. 80 (2004) 1717S-1720S
17. Clements M.R., Davies M., Hayes M.E., Hickey C.D., Lumb G.A., Mawer E.B., and Adams P.H. The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin. Endocrinol. (Oxf.) 37 (1992) 17-27
18. Cranney A., Weiler H.A., O'Donnell S., and Puil L. Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health. Am. J. Clin. Nutr. 88 (2008) 513S-519S
19. Crimmins E., Vasunilashorn S., Kim J.K., and Alley D. Biomarkers related to aging in human populations. Adv. Clin. Chem. 46 (2008) 161-216
20. de Viragh P.A., Haglid K.G., and Celio M.R. Parvalbumin increases in the caudate putamen of rats with vitamin D hypervitaminosis. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 3887-3890
21. DeLuca S., Sitara D., Kang K., Marsell R., Jonsson K., Taguchi T., Erben R.G., Razzaque M.S., and Lanske B. Amelioration of the premature ageing-like features of Fgf-23 knockout mice by genetically restoring the systemic actions of FGF-23. J. Pathol. 216 (2008) 345-355
22. Demay M.B., Kiernan M.S., DeLuca H.F., and Kronenberg H.M. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 8097-8101
23. Evatt M.L., Delong M.R., Khazai N., Rosen A., Triche S., and Tangpricha V. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch. Neurol. 65 (2008) 1348-1352
24. Eyles D.W., Smith S., Kinobe R., Hewison M., and McGrath J.J. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem. Neuroanat. 29 (2005) 21-30
25. Faupel-Badger J.M., Diaw L., Albanes D., Virtamo J., Woodson K., and Tangrea J.A. Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 2784-2786
26. Fogh K., and Kragballe K. New vitamin D analogs in psoriasis. Curr. Drug Targets Inflamm. Allergy 3 (2004) 199-204
27. Forman J.P., Curhan G.C., and Taylor E.N. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 52 (2008) 828-832
28. Forouhi N.G., Luan J., Cooper A., Boucher B.J., and Wareham N.J. Baseline serum 25-hydroxy vitamin D is predictive of future glycaemic status and insulin resistance: the MRC Ely prospective study 1990-2000. Diabetes (2008)
29. Galbiati F., Polastri L., Thorens B., Dupraz P., Fiorina P., Cavallaro U., Christofori G., and Davalli A.M. Molecular pathways involved in the antineoplastic effects of calcitriol on insulinoma cells. Endocrinology 144 (2003) 1832-1841
30. Garcion E., Nataf S., Berod A., Darcy F., and Brachet P. 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Brain Res. Mol. Brain Res. 45 (1997) 255-267
31. Garcion E., Sindji L., Montero-Menei C., Andre C., Brachet P., and Darcy F. Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25-dihydroxyvitamin D3. Glia 22 (1998) 282-294
32. Garcion E., Wion-Barbot N., Montero-Menei C.N., Berger F., and Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab. 13 (2002) 100-105
33. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., Stampfer M.J., and Willett W.C. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J. Natl. Cancer Inst. 98 (2006) 451-459
34. Gloth III F.M., Alam W., and Hollis B. Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. J. Nutr. Health Aging 3 (1999) 5-7
35. Halloran B.P., Bikle D.D., Levens M.J., Castro M.E., Globus R.K., and Holton E. Chronic 1,25-dihydroxyvitamin D3 administration in the rat reduces the serum concentration of 25-hydroxyvitamin D by increasing metabolic clearance rate. J. Clin. Invest. 78 (1986) 622-628
36. Harant H., Spinner D., Reddy G.S., and Lindley I.J. Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor. J. Cell. Biochem. 78 (2000) 112-120
37. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J.C., Thompson P.D., Selznick S.H., Dominguez C.E., and Jurutka P.W. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 13 (1998) 325-349
38. Helm S., Sylvia V.L., Harmon T., Dean D.D., Boyan B.D., and Schwartz Z. 24,25-(OH)2D3 regulates protein kinase C through two distinct phospholipid-dependent mechanisms. J. Cell. Physiol. 169 (1996) 509-521
39. Holick M.F., and Chen T.C. Vitamin D deficiency: a worldwide problem with health consequences. Am. J. Clin. Nutr. 87 (2008) 1080S-S1086
40. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., and Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358 (2001) 1500-1503
41. IARC, 2008. Vitamin D and Cancer. IARC Working Group Reports 5.
42. Irminger-Finger I. Science of cancer and aging. J. Clin. Oncol. 25 (2007) 1844-1851
43. Kalueff A., Loseva E., Haapasalo H., Rantala I., Keranen J., Lou Y.R., Minasyan A., Keisala T., Miettinen S., Kuuslahti M., and Tuchimaa P. Thalamic calcification in vitamin D receptor knockout mice. Neuroreport 17 (2006) 717-721
44. Kalueff A.V., Keisala T., Minasyan A., Kuuslahti M., Miettinen S., and Tuohimaa P. Behavioural anomalies in mice evoked by "Tokyo" disruption of the Vitamin D receptor gene. Neurosci. Res. 54 (2006) 254-260
45. Kalueff A.V., Lou Y.R., Laaksi I., and Tuohimaa P. Increased grooming behavior in mice lacking vitamin D receptors. Physiol. Behav. 82 (2004) 405-409
46. Kalueff A.V., Lou Y.R., Laaksi I., and Tuohimaa P. Abnormal behavioral organization of grooming in mice lacking the vitamin D receptor gene. J. Neurogenet. 19 (2005) 1-24
47. Kalueff A.V., Minasyan A., Keisala T., Kuuslahti M., Miettinen S., and Tuohimaa P. Increased severity of chemically induced seizures in mice with partially deleted Vitamin D receptor gene. Neurosci. Lett. 394 (2006) 69-73
48. Kalueff A.V., Minasyan A., Keisala T., Kuuslahti M., Miettinen S., and Tuohimaa P. The vitamin D neuroendocrine system as a target for novel neurotropic drugs. CNS Neurol. Disord. Drug Targets 5 (2006) 363-371
49. Kalueff A.V., Minasyan A., and Tuohimaa P. Behavioural characterization in rats using the elevated alley Suok test. Behav. Brain Res. 165 (2005) 52-57
50. Kappeler L., De Magalhaes Filho C.M., Dupont J., Leneuve P., Cervera P., Perin L., Loudes C., Blaise A., Klein R., Epelbaum J., Le Bouc Y., and Holzenberger M. Brain IGF-1 receptors control mammalian growth and lifespan through a neuroendocrine mechanism. PLoS Biol. 6 (2008) e254
51. Keisala T., Minasyan A., Jarvelin U., Wang J., Hamalainen T., Kalueff A.V., and Tuohimaa P. Aberrant nest building and prolactin secretion in vitamin D receptor mutant mice. J. Steroid Biochem. Mol. Biol. 104 (2007) 269-273
52. Keisala T., Minasyan A., Lou Y., Zou J., Kalueff A.V., Pyykkö I., and Tuohimaa P. Premature aging of vitamin D receptor mutant mice. JSBMB 115 (2009) 91-97
53. Konradsen S., Ag H., Lindberg F., Hexeberg S., and Jorde R. Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. Eur. J. Nutr. 47 (2008) 87-91
54. Kutuzova G.D., and DeLuca H.F. 1,25-Dihydroxyvitamin D3 regulates genes responsible for detoxification in intestine. Toxicol. Appl. Pharmacol. 218 (2007) 37-44
55. Laaksi I., Ruohola J.P., Tuohimaa P., Auvinen A., Haataja R., Pihlajamaki H., and Ylikomi T. An association of serum vitamin D concentrations <40 nmol/L with acute respiratory tract infection in young Finnish men. Am. J. Clin. Nutr. 86 (2007) 714-717
56. Lee C.K., Weindruch R., and Prolla T.A. Gene-expression profile of the ageing brain in mice. Nat. Genet. 25 (2000) 294-297
57. Li Y., Xu L., Shen L., Yu L., and Chen L. Relationship between glucocorticoid-induced osteoporosis and vitamin D receptor genotypes. J. Huazhong Univ. Sci. Technol. Med. Sci. 22 (2002) 317-319, 323
58. Li Y.C., Qiao G., Uskokovic M., Xiang W., Zheng W., and Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J. Steroid Biochem. Mol. Biol. 89-90 (2004) 387-392
59. Lou Y.R., Laaksi I., Syvälä H., Bläuer M., Tammela T.L., Ylikomi T., and Tuohimaa P. 25-Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. FASEB J. 18 (2004) 332-334
60. Mackay-Sim A., Feron F., Eyles D., Burne T., and McGrath J. Schizophrenia, vitamin D, and brain development. Int. Rev. Neurobiol. 59 (2004) 351-380
61. MacLaughlin J., and Holick M.F. Aging decreases the capacity of human skin to produce vitamin D3. J. Clin. Invest. 76 (1985) 1536-1538
62. Margolis K.L., Ray R.M., Van Horn L., Manson J.E., Allison M.A., Black H.R., Beresford S.A., Connelly S.A., Curb J.D., Grimm Jr. R.H., Kotchen T.A., Kuller L.H., Wassertheil-Smoller S., Thomson C.A., and Torner J.C. Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension 52 (2008) 847-855
63. Markestad T., Hesse V., Siebenhuner M., Jahreis G., Aksnes L., Plenert W., and Aarskog D. Intermittent high-dose vitamin D prophylaxis during infancy: effect on vitamin D metabolites, calcium, and phosphorus. Am. J. Clin. Nutr. 46 (1987) 652-658
64. Marshall T.G. Are statins analogues of vitamin D?. Lancet 368 (2006) 1234 (author reply 1235)
65. McGrath J., Saari K., Hakko H., Jokelainen J., Jones P., Jarvelin M.R., Chant D., and Isohanni M. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr. Res. 67 (2004) 237-245
66. Melamed M.L., Michos E.D., Post W., and Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 168 (2008) 1629-1637
67. Mimouni F.B., and Shamir R. Vitamin D requirements in the first year of life. Curr. Opin. Clin. Nutr. Metab. Care 12 (2009) 287-292
68. Minasyan A., Keisala T., Lou Y.R., Kalueff A.V., and Tuohimaa P. Neophobia, sensory and cognitive functions, and hedonic responses in vitamin D receptor mutant mice. J. Steroid Biochem. Mol. Biol. 104 (2007) 274-280
69. Minasyan A., Keisala T., Zou A., Zhang Y., Toppila E., Syvälä H., Lou Y.R., Kalueff A., Pyykkö I., and Tuohimaa P. Balance deficits in vitamin D receptor mutant mice. JSBMB 114 (2009) 161-166
70. Montero-Odasso M., and Duque G. Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. Mol. Aspects Med. 26 (2005) 203-219
71. Mooijaart S.P., Brandt B.W., Baldal E.A., Pijpe J., Kuningas M., Beekman M., Zwaan B.J., Slagboom P.E., Westendorp R.G., and van Heemst D. C. elegans DAF-12, Nuclear Hormone Receptors and human longevity and disease at old age. Ageing Res. Rev. 4 (2005) 351-371
72. Neveu I., Naveilhan P., Jehan F., Baudet C., Wion D., De Luca H.F., and Brachet P. 1,25-Dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Brain Res. Mol. Brain Res. 24 (1994) 70-76
73. Neveu I., Naveilhan P., Menaa C., Wion D., Brachet P., and Garabedian M. Synthesis of 1,25-dihydroxyvitamin D3 by rat brain macrophages in vitro. J. Neurosci. Res. 38 (1994) 214-220
74. Nykjaer A., Dragun D., Walther D., Vorum H., Jacobsen C., Herz J., Melsen F., Christensen E.I., and Willnow T.E. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96 (1999) 507-515
75. Oermann E., Bidmon H.J., Witte O.W., and Zilles K. Effects of 1alpha,25 dihydroxyvitamin D3 on the expression of HO-1 and GFAP in glial cells of the photothrombotically lesioned cerebral cortex. J. Chem. Neuroanat. 28 (2004) 225-238
76. Oliveri B., Cassinelli H., Mautalen C., and Ayala M. Vitamin D prophylaxis in children with a single dose of 150000 IU of vitamin D. Eur. J. Clin. Nutr. 50 (1996) 807-810
77. Ornoy A., Goodwin D., Noff D., and Edelstein S. 24,25-Dihydroxyvitamin D is a metabolite of vitamin D essential for bone formation. Nature 276 (1978) 517-519
78. Oudshoorn C., Mattace-Raso F.U., van der Velde N., Colin E.M., and van der Cammen T.J. Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 25 (2008) 539-543
79. Peng X., Hawthorne M., Vaishnav A., St-Arnaud R., and Mehta R.G. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res. Treat. 113 (2009) 31-41
80. Ponsonby A.L., Lucas R.M., and van der Mei I.A. UVR, vitamin D and three autoimmune diseases-multiple sclerosis, type 1 diabetes, rheumatoid arthritis. Photochem. Photobiol. 81 (2005) 1267-1275
81. Prufer K., Veenstra T.D., Jirikowski G.F., and Kumar R. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord. J. Chem. Neuroanat. 16 (1999) 135-145
82. Ranganathan P. Genetics of bone loss in rheumatoid arthritis-role of vitamin D receptor polymorphisms. Rheumatology (Oxford) (2009)
83. Razzaque M.S., Sitara D., Taguchi T., St-Arnaud R., and Lanske B. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J. 20 (2006) 720-722
84. Reinholz G.G., and DeLuca H.F. Inhibition of 25-hydroxyvitamin D3 production by 1,25-dihydroxyvitamin D3 in rats. Arch. Biochem. Biophys. 355 (1998) 77-83
85. Rimaniol J.M., Authier F.J., and Chariot P. Muscle weakness in intensive care patients: initial manifestation of vitamin D deficiency. Intensive Care Med. 20 (1994) 591-592
86. Ronnefarth G., and Misselwitz J. Nephrocalcinosis in children: a retrospective survey. Members of the Arbeitsgemeinschaft fur padiatrische Nephrologie. Pediatr. Nephrol. 14 (2000) 1016-1021
87. Rottiers V., Motola D.L., Gerisch B., Cummins C.L., Nishiwaki K., Mangelsdorf D.J., and Antebi A. Hormonal control of C. elegans dauer formation and life span by a Rieske-like oxygenase. Dev. Cell 10 (2006) 473-482
88. Rowling M.J., Kemmis C.M., Taffany D.A., and Welsh J. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J. Nutr. 136 (2006) 2754-2759
89. Ruohola J.P., Laaksi I., Ylikomi T., Haataja R., Mattila V.M., Sahi T., Tuohimaa P., and Pihlajamaki H. Association between serum 25(OH)D concentrations and bone stress fractures in Finnish young men. J. Bone Miner. Res. 21 (2006) 1483-1488
90. Schauber J., and Gallo R.L. Antimicrobial peptides and the skin immune defense system. J. Allergy Clin. Immunol. 122 (2008) 261-266
91. Schauber J., and Gallo R.L. The vitamin D pathway: a new target for control of the skin's immune response?. Exp. Dermatol. 17 (2008) 633-639
92. Schwartz G.G. Multiple sclerosis and prostate cancer: what do their similar geographies suggest?. Neuroepidemiology 11 (1992) 244-254
93. Schwartz G.G., Whitlatch L.W., Chen T.C., Lokeshwar B.L., and Holick M.F. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev. 7 (1998) 391-395
94. Scragg R., Holdaway I., Jackson R., and Lim T. Plasma 25-hydroxyvitamin D3 and its relation to physical activity and other heart disease risk factors in the general population. Ann. Epidemiol. 2 (1992) 697-703
95. Scragg R., Jackson R., Holdaway I.M., Lim T., and Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int. J. Epidemiol. 19 (1990) 559-563
96. Shea M.K., Benjamin E.J., Dupuis J., Massaro J.M., Jacques P.F., D'Agostino Sr. R.B., Ordovas J.M., O'Donnell C.J., Dawson-Hughes B., Vasan R.S., and Booth S.L. Genetic and non-genetic correlates of vitamins K and D. Eur. J. Clin. Nutr. 63 (2009) 458-464
97. Trump D.L., Hershberger P.A., Bernardi R.J., Ahmed S., Muindi J., Fakih M., Yu W.D., and Johnson C.S. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J. Steroid Biochem. Mol. Biol. 89-90 (2004) 519-526
98. Tsoukas C.D., Provvedini D.M., and Manolagas S.C. 1,25-Dihydroxyvitamin D3: a novel immunoregulatory hormone. Science 224 (1984) 1438-1440
99. Tuohimaa P. Vitamin D, aging, and cancer. Nutr. Rev. 66 (2008) S147-S152
100. Tuohimaa P. Vitamin D and aging. JSBMB 114 (2009) 78-84
101. Tuohimaa P., Tenkanen L., Ahonen M., Lumme S., Jellum E., Hallmans G., Stattin P., Harvei S., Hakulinen T., Luostarinen T., Dillner J., Lehtinen M., and Hakama M. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer 108 (2004) 104-108
102. van Driel M., Koedam M., Buurman C.J., Roelse M., Weyts F., Chiba H., Uitterlinden A.G., Pols H.A., and van Leeuwen J.P. Evidence that both 1alpha,25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization. J. Cell. Biochem. 99 (2006) 922-935
103. Van Etten E., Decallonne B., Verlinden L., Verstuyf A., Bouillon R., and Mathieu C. Analogs of 1alpha,25-dihydroxyvitamin D3 as pluripotent immunomodulators. J. Cell. Biochem. 88 (2003) 223-226
104. Wang J.H., and Tuohimaa P. Regulation of 17beta-hydroxysteroid dehydrogenase type 2, type 4 and type 5 by calcitriol, LXR agonist and 5alpha-dihydrotestosterone in human prostate cancer cells. J. Steroid Biochem. Mol. Biol. 107 (2007) 100-105
105. Wang Y., Chiang Y.H., Su T.P., Hayashi T., Morales M., Hoffer B.J., and Lin S.Z. Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 39 (2000) 873-880
106. Wenzel U. Nutrition, sirtuins and aging. Genes Nutr. 1 (2006) 85-93
107. Westendorp R.G., and Kirkwood T.B. Human longevity at the cost of reproductive success. Nature 396 (1998) 743-746
108. White P., and Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol. Metab. 11 (2000) 320-327
109. Wilkins C.H., Sheline Y.I., Roe C.M., Birge S.J., and Morris J.C. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am. J. Geriatr. Psychiatry 14 (2006) 1032-1040
110. Zehnder D., Bland R., Williams M.C., McNinch R.W., Howie A.J., Stewart P.M., and Hewison M. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 86 (2001) 888-894
111. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence?. Br. J. Nutr. 89 (2003) 552-572
112. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog. Biophys. Mol. Biol. 92 (2006) 39-48
113. Zittermann A., and Koerfer R. Vitamin D in the prevention and treatment of coronary heart disease. Curr. Opin. Clin. Nutr. Metab. Care 11 (2008) 752-757
114. Zittermann A., Schleithoff S.S., and Koerfer R. Vitamin D insufficiency in congestive heart failure: why and what to do about it?. Heart Fail. Rev. 11 (2006) 25-33
115. Zou J., Minasyan A., Keisala T., Zhang Y., Wang J.H., Lou Y.R., Kalueff A., Pyykko I., and Tuohimaa P. Progressive hearing loss in mice with a mutated vitamin D receptor gene. Audiol. Neurootol. 13 (2008) 219-230